Geriatric-8 (G8) screening tool stratified the efficacy of S-1 plus ramucirumab in elderly patients with advanced/recurrent gastric cancer: A post-hoc analysis of the KSCC1701 trial

被引：1

作者：

Hu, Qingjiang

Suyama, Koichi

Kobayashi, Kazuma

Katsuya, Hiroo

Izawa, Naoki

Uenosono, Yoshikazu

Kusumoto, Tetsuya

Otsu, Hajime

Orita, Hiroyuki

Kawanaka, Hirofumi

Shibao, Kazunori

Koga, Satoshi

Shimokawa, Mototsugu

Makiyama, Akitaka

Saeki, Hiroshi

Oki, Eiji

Baba, Hideo

Mori, Masaki

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[2] Toranomon Gen Hosp, Dept Med Clin Oncol, Tokyo, Japan

[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan

[4] Saga Univ, Div Hematol Resp Med & Oncol, Dept Internal Med, Fac Med, Saga, Japan

[5] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

[6] Imamura Gen Hosp, Dept Surg, Kagoshima, Japan

[7] Natl Kyushu Med Ctr, Dept Surg Gastroenterol, Beppu, Oita, Japan

[8] Natl Kyushu Med Ctr, Clin Res Inst, Canc Res Div, Beppu, Oita, Japan

[9] Kyushu Univ, Dept Surg, Beppu Hosp, Beppu, Oita, Japan

[10] Nakatsu Municipal Hosp, Dept Surg, Nakatsu, Japan

[11] Natl Hosp Org Beppu Med Ctr, Clin Res Inst, Beppu, Oita, Japan

[12] Natl Hosp Org Beppu Med Ctr, Dept Surg, Beppu, Oita, Japan

[13] Hosp Univ Occupat & Environm Hlth, Dept Surg 1, Kitakyushu, Fukuoka, Japan

[14] Iizuka Hosp, Dept Surg, Iizuka, Fukuoka, Japan

[15] Yamaguchi Univ, Grad Sch Med, Dept Biostat, Ube, Yamaguchi, Japan

[16] Gifu Univ Hosp, Ctr Canc, Kitakyushu, Fukuoka, Japan

[17] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Maebashi, Gumma, Japan

[18] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto, Japan

[19] Tokai Univ, Hiratsuka, Kanagawa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.256

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

256

引用

页数：3

共 9 条

[1] A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).
Katsuya, Hiroo
Suyama, Koichi
Kobayashi, Kazuma
Izawa, Naoki
Uenosono, Yoshikazu
Hu, Qingjiang
Kusumoto, Tetsuya
Otsu, Hajime
Orita, Hiroyuki
Kawanaka, Hirofumi
Shibao, Kazunori
Koga, Satoshi
Shimokawa, Mototsugu
Makiyama, Akitaka
Saeki, Hiroshi
Oki, Eiji
Baba, Hideo
Mori, Masaki
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] A phase II multicenter trial assessing the efficacy and safety of first-line S-1 thorn ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701
Kobayshi, Kazuma
Suyama, Koichi
Katsuya, Hiroo
Izawa, Naoki
Uenosono, Yoshikazu
Hu, Qingjiang
Kusumoto, Tetsuya
Otsu, Hajime
Orita, Hiroyuki
Kawanaka, Hirofumi
Shibao, Kazunori
Koga, Satoshi
Shimokawa, Mototsugu
Makiyama, Akitaka
Saeki, Hiroshi
Oki, Eiji
Baba, Hideo
Mori, Masaki
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 166 : 279 - 286
[3] COMBINATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AND G8 SCREENING TOOL IS USEFUL TO PREDICT OVERALL SURVIVAL OF ELDERLY PATIENTS WITH CHEMOTHERAPY FOR UNRESECTABLE/RECURRENT GASTRIC CANCER
Kitayama, Yoshitaka
Tozawa, Katsuyuki
Fukui, Hirokazu
Hara, Ken
Kondo, Takashi
Tomita, Toshihiko
Ohda, Yoshio
Oshima, Tadayuki
Watari, Jiro
Miwa, Hiroto
[J]. GASTROENTEROLOGY, 2018, 154 (06) : S934 - S934
[4] Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
Ishida, Hiroo
Sunakawa, Yu
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Kakeji, Yoshihiro
Sano, Takeshi
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 371 - 371
[5] Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: A subgroup analysis from the phase III JFMC36-0701 trial
Nishikawa, K.
Yoshino, S.
Morita, S.
Takahashi, T.
Sakata, K.
Nagao, J.
Nemoto, H.
Murakami, N.
Hasegawa, H.
Shimizu, R.
Yoshikawa, T.
Osanai, H.
Imano, M.
Naitoh, H.
Tanaka, A.
Sakamoto, J.
Saji, S.
Oka, M.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[6] Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World Analysis
Zurlo, Ina Valeria
Pozzo, Carmelo
Strippoli, Antonia
Mignogna, Samantha
Basso, Michele
Vivolo, Raffaella
Trovato, Giovanni
Ciaburri, Michele
Morelli, Franco
Bria, Emilio
Leo, Silvana
Tortora, Giampaolo
[J]. GERIATRICS, 2022, 7 (05)
[7] Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)
Kashiwada, Tomomi
Shinozaki, Katsunori
Ueno, Shohei
Kawanaka, Hirofumi
Uno, Futoshi
Okita, Yoshihiro
Fukahori, Masaru
Matsushita, Hidenobu
Emi, Yasunori
Shimokawa, Mototsugu
Makiyama, Akitaka
Saeki, Hiroshi
Oki, Eiji
Maehara, Yoshihiko
Mori, Masaki
Baba, Eishi
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (02) : 345 - 354
[8] Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)
Tomomi Kashiwada
Katsunori Shinozaki
Shohei Ueno
Hirofumi Kawanaka
Futoshi Uno
Yoshihiro Okita
Masaru Fukahori
Hidenobu Matsushita
Yasunori Emi
Mototsugu Shimokawa
Akitaka Makiyama
Hiroshi Saeki
Eiji Oki
Yoshihiko Maehara
Masaki Mori
Eishi Baba
[J]. International Journal of Clinical Oncology, 2021, 26 : 345 - 354
[9] Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Boku, N.
Ryu, M. -H.
Kato, K.
Chung, H. C.
Minashi, K.
Lee, K. -W.
Cho, H.
Kang, W. K.
Komatsu, Y.
Tsuda, M.
Yamaguchi, K.
Hara, H.
Fumita, S.
Azuma, M.
Chen, L. -T.
Kang, Y. -K.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (02) : 250 - 258

← 1 →